anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PTP1B inhibitors with the following structure (formula I). Experiments indicate that these inhibitors can effectively inhibit the activity of protein tyrosine phosphatase 1B (PTP1B). They can be used as insulin sensitisers. They can be used to prevent, delay or treat diseases which are related to insulin antagonism mediated by PTP1B, especially diabetes type II  and obesity. The invention also provides methods for preparing these inhibitors. (see formula I)
Eligible subjects will receive GSK961081 (400 micrograms or 1200 micrograms), GSK961081 matching placebo, propranolol (80 milligrams) and propranolol matching placebo in five treatment sessions through ten different crossover treatment sequences. There will be a washout period between treatment sessions of 7 to 14 days.
The invention discloses a Chinese herbal medicine decoction and a decocting method thereof. The Chinese herbal medicine decoction is a water solution of medicines, which is obtained by decocting various Chinese herbal medicines in water, and the Chinese herbal medicine decoction can be orally taken and externally used at the same time. The decocting method comprises the steps of placing 12g of dried radix berberidis, 15g of dried paederia scandens, 15g of dried nepal dock roots, 9g of dried ageratina adenophora and 9g of dried artemisia argyi into a ceramic vessel, adding 1000ml of water to boil, controlling the fire to be slightly big before boiling, and then, boiling on small fire after boiling; and when reducing the water volume to about 200ml, pouring out water in which Chinese herbal medicine components are dissolved to obtain the decoction in a Chinese herbal medicine preparation. The Chinese herbal medicine decoction can be drunk when being placed to the proper temperature. The decoction can also be decocted more according to a certain ratio, wherein one part of the decoction is used for drinking, and the other part of decoction is used for scrubbing an inflammatory part, so that the effect is better. The Chinese herbal medicine decoction for diminishing inflammation and relieving pain can be orally taken and can also be externally used for scrubbing.
Reproduction toxicity studies have been performed in pregnant New Zealand white rabbits and Sprague‑Dawley rats. During gestation days 6 to 18, rabbits received 1.3, 4.2, or 13 mg/kg/day subcutaneously. In rats, subcutaneous doses of 5.3, 11 and 26 mg/kg/day were administered during gestation days 6 to 15. No teratogenic effects were observed in rats and rabbits at the highest doses tested. The highest doses of 13 mg/kg/day (rabbits) and 26 mg/kg/day (rats) are approximately 1/3 of the maximum recommended human dose (epidural, 770 mg/24 hours) based on a mg/m2 basis. In 2 prenatal and postnatal studies, the female rats were dosed daily from day 15 of gestation to day 20 postpartum. The doses were 5.3, 11 and 26 mg/kg/day subcutaneously. There were no treatment‑related effects on late fetal development, parturition, lactation, neonatal viability, or growth of the offspring. 

In another study with rats, the males were dosed daily for 9 weeks before mating and during mating. The females were dosed daily for 2 weeks before mating and then during the mating, pregnancy, and lactation, up to day 42 post coitus. At 23 mg/kg/day, an increased loss of pups was observed during the first 3 days postpartum. The effect was considered secondary to impaired maternal care due to maternal toxicity. 

There are no adequate or well‑controlled studies in pregnant women of the effects of ropivacaine hydrochloride on the developing fetus. Ropivacaine hydrochloride should only be used during pregnancy if the benefits outweigh the risk. 

Teratogenicity studies in rats and rabbits did not show evidence of any adverse effects on organogenesis or early fetal development in rats (26 mg/kg sc) or rabbits (13 mg/kg). The doses used were approximately equal to total daily dose based on body surface area. There were no treatment‑related effects on late fetal development, parturition, lactation, neonatal viability, or growth of the offspring in 2 perinatal and postnatal studies in rats, at dose levels equivalent to the maximum recommended human dose based on body surface area. In another study at 23 mg/kg, an increased pup loss was seen during the first 3 days postpartum, which was considered secondary to impaired maternal care due to maternal toxicity.
Systems, methods and computer program products to identify and close gaps in care are provided. Aspects of the present disclosure disclosed and described herein enable a payer may identify gaps in care based on information in the payer database. The payer can send this information to the provider prior to patient scheduling. The scheduling system at the provider can use this information to schedule patients and their medical needs (e.g., medical test, lab tests, imaging tests, etc.) before the next patient appointment. Primary care providers (PCPs) can then be made aware of the gaps in care information, as well as Hierarchical Condition Category (HCC) coding gap information, so they can perform a complete diagnosis using all available clinical data. PCP notes along with the treatment the patient receives can be combined with the RAF (Risk Adjustment Score) shared by the payers to ensure patient is assessed for all relevant conditions during the visit. Payers can then be informed electronically that the gap in care has been closed; the payer can also receive the resultant claims such that correct RAF scores can be computed and HCC coding gaps can be closed.
A pharmaceutical composition having antidiabetic activity in a form suitable for oral administration, e.g. tablet, powder or capsule, comprises at least 25 mg. of dicyclopropyl ketazine and a solid non-toxic pharmaceutical carrier.  The carrier may form the container for the dicyclopropyl ketazine as in the case of gelatin in a gelatin capsule.  The solid composition may contain binding agents, diluents and tabletting adjuvants, e.g. corn starch, acacia, lactose, talc, stearic acid, magnesium stearate and gums. The composition may take the form of a liquid comprising a liquid pharmaceutical carrier, e.g. water, containing at least 5 mg./c.c. of dicyclopropyl ketazine with a minimum of 25 mg. of dicyclopropyl ketazine, with a preservative and/or flavouring agent or agents and/or one or more non-toxic suspending agents, e.g. acacia, carboxymethyl cellulose, sodium carboxymethyl cellulose, and esters of p-hydroxybenzoic acid.
Participants will receive cannabidiol, starting at 100 mg twice daily, and increased to 200 mg twice daily by week 3. This arm will last six weeks.
Preterm infants differ significantly from their term infant counterparts regarding bacterial colonization patterns related to maternal microbiota diversity, mode of delivery, feeding type, antibiotic exposure, and the environmental influences related to prolonged hospitalization in the neonatal intensive care unit (NICU). Necrotizing enterocolitis (NEC), a multifactorial intestinal disorder characterized by ischemic bowel disease, disproportionately impacts preterm infants and has a high disease burden. Recent studies in the basic, translational, and clinical scientific literature have advanced knowledge into this complex disease process. Despite the explosion of research into NEC, however, there is a still a great deal unknown about this devastating illness. Additionally, the disease morbidity and mortality for NEC remain high despite advances in therapy options. This chapter reviews the current literature into the preterm infant microbiome, pathogenesis of NEC, potential targets for altering preterm microbiome, influence of microbiome on other organ systems, long-term implications of microbiome dysbiosis, and future directions of study.
FIELD: food industry. SUBSTANCE: invention relates to methods of preparing bacterial ferments for production of fermented-milk products using lactic acid bacteria. Method of preparing bacterial ferment for fermented-milk product involves preparing the nutrient medium based on enzymatic hydrolyzate of protein component, seeding bifidobacteria and/or lactobacillum bacteria, and/or lactic acid streptococci on sterile nutrient medium and their culturing. Soybean milk is used as the source of the protein component for hydrolyzate preparing and pepsin is used as an enzyme. Hydrolysis is carried out at pH = 1.5-4.5 for 4 h. Process of hydrolysis of soybean milk does not require the constant control over pH medium. Method provides increase titer value of viable cultures to 10 20 . Antagonistic activity of ferment with respect to pathogenic and opportunistic intestine microflora is increased. Ferment storage time is increased to 30 days. EFFECT: simplified method, broadened raw base, enhanced curative properties of ferment. 2 tbl, 1 ex
This cohort is for patients without refractory/relapsed B-cell NHL or leukemia (ALL). Three dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.
All patients will undergo cerebrospinal fluid (CSF) and blood collection as well as MRI imaging as standard of care prior to (- 21 days) first-line treatment initiation, during first-line therapy (before initiation of the 5th methotrexate dose (+/- 7 days)), at completion of first-line chemotherapy therapy (+/- 7 days) as well as 60, 180, and 360 days after enrollment into maintenance or observation (+/- 7 days). Those patients with persistent cfDNA in the CSF after completion of first-line chemotherapy and either complete or partial response on imaging will be enrolled into the nivolumab maintenance treatment arm. All other patients (no persistent cfDNA in the CSF and either complete or partial response on imaging) are followed with observation. Patients who do not respond to first-line therapy are not eligible for nivolumab maintenance and will no longer be followed in the biospecimen and clinical data collection cohort.
Inflammation plays an important role in the process of cancer development. The number of studies evaluating the ability of inflammatory biomarkers to predict survival has increased in recent years. This study aimed to comprehensively evaluate the predictive role of inflammatory biomarkers in patients with larynx cancer undergoing definitive radiotherapy. A total of 101 patients who underwent definitive radiotherapy for larynx cancer at our center were retrospectively examined. Blood samples were taken from the patients before radiotherapy to obtain biomarkers such as C-reactive protein (CRP), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), pan-immune inflammatory value (PIV), hemo-eosinophil inflammation index (HEI), albumin, and Lactate dehydrogenase (LDH). The study examined the predictive value of parameters for progression-free survival (PFS), local recurrence-free survival (LRFS), and overall survival (OS) using both univariate and multivariate Cox regression analysis. In the univariate analysis, the biomarkers that predicted PFS were SII, PIV, CRP, and Eastern Cooperative Oncology Group Performance Status (ECOG PS). According to the multivariate analysis, only CRP was found to be a significant predictor of PFS. In the univariate analysis, the following biomarkers were found to predict OS: NLR, PLR, MLR, SII, PIV, CRP, HEI, stage, and ECOG PS. In the multivariate analysis, NLR and ECOG PS were found to be predictors of OS. A significant difference was found in MLR, PIV, and CRP values based on the presence of lymphatic metastasis. The current study is the first to comprehensively examine the relationship between larynx cancer and several inflammatory biomarkers. Many of these biomarkers have been shown to predict both PFS and OS in patients with larynx cancer undergoing definitive radiotherapy. It has been shown that PIV and CRP may predict the presence of lymphatic metastases in addition to PFS and OS.
Anthelmintic preparations are made by mixing chenopodium oil or fern extract with an adsorbent, such as medicinal carbon or kieselguhr, in such relative quantity that when a dose containing more than the lethal quantity of the active drug is administered to an animal the quantity of the drug liberated from the absorbent into the intestinal fluid is not sufficient to produce a toxic effect on the animal but is fatal to the parasites.  According to examples: (1) 3 drops of chenopodium oil are adsorbed by 0,25 gm. of carbon and (2) fern extract is adsorbed into carbon and made into sugar coated tablets or pills variously coloured according to the content of the active drug. The Specification as open to inspection under Sect. 91 refers also to remedies for intestinal disinfection; refers to the use of p. cymol dissolved in carbontetrachloride, and of creosote as active drugs; is not limited to the proportions in which the ingredients are mixed; and contains additional examples, according to one of which additional carbon is added to a mixture of chenopodium oil with carbon, and according to another ten parts of diatomaceous earth are caused to absorb 5 parts of extract of ferns and thirty per cent of this extract is then removed by means of an organic solvent.  This subject-matter does not appear in the Specification as accepted.
A system and method for image processing are provided. A pre-processed image may be obtained. The pre-processed image may be decomposed into a low-frequency image and a high-frequency image. At least one grayscale transformation range may be determined based on the low-frequency image. At least one grayscale transformation parameter may be determined based on the at least one grayscale transformation range. The low-frequency image may be transformed based on the at least one grayscale transformation parameter to obtain a transformed low-frequency image. A transformed image may be generated by reconstructing the transformed low-frequency image and the high-frequency image.
FIELD: medicine, stomatology. SUBSTANCE: agent is made of the combined hydrophobic and hydrophilic layers. Hydrophobic layer consists of polyvinylbutyral and plasticizer Tween at their ratio = 9:1 and hydrophilic layer consists of polyvinyl alcohol and plasticizer polyethylene glycol at their ratio = 9: 1. Molecular mass of polyethylene glycol is 400-4000 Da. Agent is made as a film that contains antibiotics and/or sulfanilamide preparations, and/or preparations of imidazole group, and/or cationic surface-active substances, and/or medicinal plant extracts with the use of the indicated biologically active substances or in mixture with vitamins, essential oils. EFFECT: broadened arsenal of medicinal agents of the prolonged action.
This invention provides a system and method for assessing risk of a breast cancer diagnosis based upon imagery of tissue and (optionally) other patient-related factors. A CAD (or similar) system analyzes the imagery and generates a plurality of numerical feature values. An assessment module receives inputs from patient factors and history and computes the risk based upon the feature values and the patient factors and history. A masking module receives inputs from the patient factors and history, and computes the risk of having a cancer, which cancer is otherwise characterized by a low probability of detection, based upon the feature values and the patient factors and history. A recall module receives inputs from the assessment module and the masking assessment module, and generates a computer-aided indication of a clinical follow-up by the patient. Results of assessment(s) can be displayed to the clinician and/or patient using a graphical interface display.
A composition comprising the extract of Corallina sp. is provided to exhibit antifungal activity against Malassezia sp. which is a fungus causing dandruff or atopic dermatitis without side effects, so that the composition is useful for preventing or treating dandruff or atopic dermatitis. A composition exhibiting antifungal activity against Malassezia sp. selected from Malassezia furfur, Malassezia restricta, Malassezia obtusa, Malassezia globosa, Malassezia slooffiae, Malassezia sympodialis and Malassezia pachydermatis comprises the extract of Corallina sp. including Corallina pilulifera and Corallina officinalis, which is prepared by extracting Corallina sp. with an extraction solvent selected from ether, chloroform, benzene, hexane, dichloromethane and a mixture thereof.
ESP block (Group ESP) will be performed in the preoperative block room. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
Mindfulness-Based Cognitive Therapy (MBCT), developed by Zindel Segal, Mark Williams and John Teasdale, employs a cognitive theoretical framework (Cullen, 2011; Segal, Williams, \& Teasdale, 2002). It is also delivered as an eight-session group treatment. The first four sessions teach the fundamental concepts and skills of the practice of mindfulness. The remaining four sessions teach the individual how to notice his/her own thoughts and the impact of such thoughts on his/her own physical and emotional experiences.
Therapeutic hypothermia is the standard treatment for hypoxic-ischemic encephalopathy (HIE), but despite its widespread use, the rates of mortality and neurodevelopmental impairment for moderate to severe HIE remain around 30%. Methylxanthines, such as caffeine and aminophylline, have potential neuroprotective effects in the setting of hypoxic-ischemic injury. However, data on the safety and efficacy of methylxanthines in the setting of therapeutic hypothermia for HIE are limited. This retrospective multicenter study examined in-hospital outcomes in 52 infants with HIE receiving methylxanthines and therapeutic hypothermia. The frequency of mortality and in-hospital morbidities were similar to those of infants enrolled in clinical trials undergoing therapeutic hypothermia without adjunctive therapies. Clinical trials of methylxanthines for neuroprotection in HIE are needed to determine safety and efficacy and should explore optimal dosing and timing of methylxanthine administration.
PURPOSE:To obtain a new compound useful for improving general symptoms and suppressing alternation and necrosis of bone and cartilago especially in chronic inflammatory diseases, having excellent anti-inflammatory action, antipyretic action and analgesic action and low toxicity. CONSTITUTION:2-(2,2-Dimethyl-8-fluorochroman-6-yl)propionic acid of the formula or its salt. The compound is obtained by catalytically reducing 2-(2,2-dimethyl-8- fluoro-1,2-benzopyran-6-yl) propionic acid in a solvent (e.g. ethyl acetate) in the presence of a catalyst (e.g. Pd-active carbon). The compound has a new structure and medicinal effect different from those of conventional acidic nonsteroid antiinflammatory agent, much more strongly suppresses destruction of bone and cartilago and basically treats. The compound, for example, is effective for treating general acute inflammatory diseases such as lumbago, toothache, pharyngitis and cystitis and chronic inflammatory diseases such as nodose rheumatism and osteoarthritis.
Using a 3 + 3 trial design, bortezomib dose exploration was performed to determine the stage 2 bortezomib dose. The number of participants at this stage is 6-9.
FIELD: medicine, pharmacology, pharmacy. SUBSTANCE: ointment has the following components taken at definite amounts: anhydrous lanolin, inner fat, bee wax, carophylene, cinquefoil rhizomes an aqueous-spirituous extract, Sophora japonica an aqueous-spirituous extract, milfoil herb an aqueous-spirituous extract, propolis spirituous extract, vegetable oil. Ointment provides wound-healing, anti-inflammatory, bactericidal and antiallergic effect and can be used for skin sicknesses treatment and in gynecology and proctology also. Ointment shows the enhanced penetrating capacity into biotissues and tissue healing and retains biologically active properties for 2 years, not less. EFFECT: enhanced effectiveness of an ointment, prolonged effect, broadened pattern of effect. 1 tbl, 7 ex
Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
Probiotics are live microorganisms that have been associated with health benefits. However, probiotic effects have not been shown to persist beyond discontinuation of use in adults. The intake of probiotics during the critical window of gut microbiota development in young children, however, may allow for a longer duration of persistence of probiotic bacteria and more stable changes in microbial composition possibly resulting in stable engraftment of the probiotic strains. This study aims is to examine the effect of a 14-day course of a commercially available probiotic yogurt drink on the composition, diversity, and changes in immune biomarkers (e.g. human beta-defensin-2 and calprotectin) of the gut microbiota of healthy children. As well, to assess whether the probiotic strains persists after discontinuation of intake and whether engraftment occurs. By understanding the impact of probiotics on the gut microbiota, we will better understand the mechanism by which probiotics exert their beneficial effects. This may help guide probiotic selection based on the potential short- and long-term effects on the commensal microbiota.
A composition for encapsulation in a soft gelatin shell, the composition comprising ibuprofen, one or more polyvinylpyrrolidones, and one or more polyethylene glycols (PEG). The weight ratio of the ibuprofen to one or more polyvinylpyrrolidones is from 2:1 to 15:1. The weight ratio of the ibuprofen to one or more polyethylene glycols is from 1:1 to 5:1. The weight ratio of the one or more polyethylene glycols to one or more polyvinylpyrrolidones is 1:1 to 10:1. The composition can comprise a hydroxide, water, and one or more polyoxysorbitan esters. The polyvinylpyrrolidones can have a molecular weight of from about 2,000 to about 5,000. The composition can have a weight of 440 to 480 mg. The dose volume of the composition can be from about 0.4 ml to about 1.0 ml. The composition can have a release rate of ibuprofen of at least 5%, 10% or 20% in 5 minutes. A further aspect of the invention is a soft gel capsule containing a composition comprising ibuprofen and a solvent system. The solvent system comprising one or more polyethylene glycols, one or more polyvinylpyrrolidones, potassium hydroxide, one or more polyoxysorbitan esters, and water.